Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an antibody fight both psoriasis and heart disease?

NCT ID NCT04776629

Disease control Sponsor: Abcentra Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a drug called orticumab in 77 adults with moderate-to-severe psoriasis who also had cardiometabolic risks (like obesity and high cholesterol). The goal was to see if orticumab could safely reduce skin plaques and inflammation linked to heart disease. Participants received either the drug or a placebo, and researchers measured changes in psoriasis severity and other health markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
orticumab (a lab-made antibody targeting oxidized LDL)
What this could lead to
If it works, this could point toward a treatment that helps both psoriasis skin symptoms and related heart disease risks.
What could go wrong
This is a small, early-phase proof-of-activity study, not a large confirmatory trial. The drug may not improve psoriasis or heart markers, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

77 people

The number who actually took part.

Started

Jun 2021

Finished

Nov 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Stable/chronic plaque psoriasis with PASI score of ≥ 12 AND involving ≥ 10% of the subject's BSA.- ≥ 30 years of age at time of consent. * BMI ≥ 30 kg/m2 * LDL ≥ 100 mg/dL at Screening. * All females must have a negative serum pregnancy test result at Screening and a negative urine pregnancy test prior to dosing. Exclusion Criteria: Subjects are excluded from the study if any of the following criteria are met: * Past use of orticumab. * Any of the nonplaque forms of psoriasis: erythrodermic, guttate, or pustular. * Scalp, palmar or plantar psoriasis only, at Screening or Baseline. * Have evidence of skin conditions (e.g., eczema) at the time of Screening or Baseline visit that would interfere with theevaluation of psoriasis. * Newly discovered Type 2 diabetes mellitus (T2DM) * Moderate or high-intensity statin use or new use of a low-intensity statin therapy. * No use of anti-coagulating or anti-thrombotic agents. * Poorly controlled hypertension * Use of an IL-23 blocker in the past 180 days, an IL-17 blocker in the past 16 weeks, or a TNF blocker in the past 12 weeks. * Use of methotrexate, cyclosporine, or apremilast in the past 4 weeks. * History of hypersensitivity or allergies to any contents in the orticumab formulation. * A history of any clinically important abnormalities in cardiac rhythm or conduction. * A history of prolonged QT intervals or a family history of long QT-syndrome at Screening. * A history of first, second or third-degree atrioventricular (AV) block, or AV dissociation. * A history of complete bundle branch block. * Unstable angina pectoris, myocardial infarction, transient ischemic attack, or stroke within 3 months prior to Screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within 6 months prior to Screening or who are due to undergo these procedures at the time of Screening. * Severe congestive heart failure (NYHA III or IV).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiometabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome coronary artery disorder Inflammation inflammatory disease metabolic syndrome X psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiometabolic syndrome Coronary artery disease Inflammation Psoriasis

Contacts and locations

Locations

  • Blue Coast Research Center

    Vista, California, 92083, United States

  • CCT Research - Springville Dermatology

    Springville, Utah, 84663, United States

  • CCT- Research at the center for Dermatology and Plastic Surgery

    Scottsdale, Arizona, 85260, United States

  • Center for Clinical Studies, LTD.LLP

    Webster, Texas, 77598, United States

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana, 46250, United States

  • Derm Institute & Skin Care Ctr., Inc.

    Santa Monica, California, 90404, United States

  • Excel Clinical Research

    Las Vegas, Nevada, 89109, United States

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida, 32216, United States

  • Las Vegas Clinical Trials

    Las Vegas, Nevada, 89030, United States

  • Orange County Research Center

    Tustin, California, 92780, United States

  • SMS Clinical Research

    Mesquite, Texas, 75149, United States

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas, 78218, United States

  • Vital Prospects Clinical Research Institute, PC

    Tulsa, Oklahoma, 85260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.